Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (not Palisade Bio, Inc.) for the reporting period of September 27, 2012. The company is a Delaware corporation headquartered in Rockville, Maryland, focused on stem cell therapies.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a Current Report (Form 8-K) detailing a specific corporate event rather than a periodic financial statement.
Material Changes
The primary material event reported is the regulatory approval received on September 27, 2012, to commence a clinical trial in China. Key details include:
- Therapeutic Area: Treatment of motor deficits due to ischemic stroke.
- Product: Spinal cord stem cells (NSI-566).
- Location: BaYi Brain Hospital in Beijing, China.
- Entity: Conducted through the subsidiary, Neuralstem China (Suzhou Neuralstem Biopharmaceutical Company, Ltd.).
Outlook, Risks, and Management Commentary
Management commentary is limited to the announcement of the trial approval. The filing does not contain specific forward-looking guidance, risk factors, or contingencies beyond the standard implications of commencing a clinical trial. A press release dated September 27, 2012, is attached as Exhibit 99.01 for further details.
Investor Verification Checklist
- Verify the specific protocol and endpoints of the NSI-566 clinical trial at BaYi Brain Hospital.
- Confirm the operational status and regulatory standing of the Suzhou Neuralstem Biopharmaceutical Company, Ltd. subsidiary.
- Review the attached press release (Exhibit 99.01) for additional details on trial enrollment and timelines.
- Check subsequent filings for updates on trial initiation and patient recruitment.